Background: Few articles have documented regimens and timing of perioperative chemotherapy for bladder cancer in routine practice. Here, we describe practice patterns in the general population of Ontario, Canada.
introduction
Utilization rates of neoadjuvant (NACT) and adjuvant (ACT) chemotherapy for muscle-invasive bladder cancer (MIBC) have been well described in a variety of population-based settings [1] [2] [3] [4] [5] . Practice guidelines recommend cisplatin-based NACT [6, 7] based on the results of clinical trials which show improved survival [8, 9] . Paradoxically, despite no level 1 evidence ACT is used more commonly than NACT in routine clinical practice [1, 4] . A recent meta-analysis of RCTs and two observational studies suggest that ACT may improve patient outcomes [4, 10, 11] . Few articles have documented the regimens used, and the timing of perioperative chemotherapy in routine clinical practice. For early-stage breast and colon cancer, where there is strong evidence to support the use of ACT, the time between surgery and initiating ACT is associated inversely with overall (OS) and cancer-specific survival (CSS) [12] [13] [14] . We are unaware of studies describing the timing of ACT initiation among patients with MIBC and whether this interval is associated with outcome.
Here, we present a population-based study in Ontario, Canada. The primary objectives were to describe chemotherapy regimens used in the perioperative setting for patients with MIBC in the general population and to explore whether the interval between cystectomy and starting ACT is associated with patient outcome.
methods study design and population
This report represents a substudy of a larger population-based, retrospective cohort study that described management and outcome of all patients with MIBC in the Canadian province of Ontario. Detailed methods and primary results have been reported elsewhere [4] . Ontario has a population of ∼13.5 million people and a single-payer universal health insurance program.
All incident cases of bladder cancer in Ontario who underwent cystectomy in 1994-2008 were identified using the Ontario Cancer Registry (OCR) and linked treatment records. The primary study population of the current report includes all patients with muscle-invasive urothelial cancer treated with cystectomy. The study was approved by the Research Ethics Board of Queen's University.
data sources
The OCR is a passive, population-based cancer registry that captures diagnostic and demographic information on at least 98% of all incident cases of cancer diagnosed in the province of Ontario [15] . Complete information about vital status was available up to 31 December 2010 and cause of death was available up to 31 December 2008. Indicators of the socioeconomic status of the community in which patients resided at the time of diagnosis were linked to the OCR as described previously [16] .
A variety of electronic administrative health databases were linked to the OCR. Records of hospitalization from the Canadian Institute for Health Information (CIHI) provided information about surgical interventions. Hospital participation in collection of separation records is known to be consistent and complete throughout Ontario [17] . Utilization of perioperative chemotherapy (any NACT or ACT) was identified from provincial physician billing records and treatment records from Ontario's regional cancer centers. Drug names and regimens were available for those cases treated at the regional comprehensive cancer centers. Surgical pathology reports were obtained from the OCR.
definitions
Co-morbidity was classified using the modified Charlson Index based on all noncancer diagnoses recorded during any hospital admission within 5 years before surgery [18] . NACT was defined as any chemotherapy administered within 16 weeks before surgery. Adjuvant therapy was defined as any chemotherapy administered within 16 weeks after surgery. The time to adjuvant chemotherapy (TTAC) was defined as the interval between cystectomy and first chemotherapy treatment. Cases that initiated ACT more than 12 weeks after surgery were classified as having delayed TTAC. Twelve weeks was chosen as the cut point based on the fact that the relevant RCTs initiated ACT before this point in time and, in our clinical practice, many oncologists prefer to start ACT within 12 weeks of surgery. Patients treated with NACT and/or postoperative RT were not included in the TTAC analysis.
statistical analysis
Factors associated with TTAC >12 weeks were evaluated by logistic regression; linear regression was used to evaluate TTAC as a continuous variable. OS and CSS were determined from cystectomy using the Kaplan-Meier method and comparisons between groups were made using the log-rank test. Factors associated with OS/CSS were evaluated using the Cox proportional hazards regression model. TTAC was evaluated as a categorical and a continuous variable. Survival analyses were restricted to patients that did not receive NACT or preoperative radiotherapy; because information about pathologic stage for these patients would not be reliable. Results were considered statistically significant at P value <0.05. As per institutional policy, small cells (one to five patients) are not reported. All analyses were carried out using SAS version 9.1 (SAS Institute, Cary, NC).
results study population and practice patterns As previously reported, 2944 patients with MIBC underwent cystectomy in Ontario during 1994-2008 [4] . Most patients (60%) were over the age of 70 and 75% were male. Locally advanced (T3/T4) tumors were present in 71% of patients and 26% of patients had positive lymph nodes. During the study period, 4% (129/2944) of patients received NACT and 19% (571/2944) of patients were treated with ACT. Thirty patients (1%) were treated with NACT and ACT. Characteristics of the 670 patients treated with NACT or ACT are shown in Table 1 .
Chemotherapy regimen was identifiable for 308/670 (46%) of patients treated with NACT/ACT. Treatment included cisplatin or carboplatin in 82% (253/308) and 14% (43/308) of patients, respectively; 4% (12/308) of patients were treated with other regimens. Patients treated with carboplatin were older (mean age 70 versus 63 years, P < 0.001) than those treated with cisplatin. There was no statistically significant difference in co-morbidity. The most commonly used regimens were gemcitabine-cisplatin (166/308, 54%), methotrexate, vinblastine, doxorubicin, cisplatin (MVAC) (66/308, 21%), gemcitabinecarboplatin (28/308, 9%) and CMV (15/308, 5%). 
timing of ACT
Among the 541 cases with ACT alone, 8 were treated with postoperative RT and were therefore removed from the TTAC analyses. Time from cystectomy to initiation of ACT among the remaining 533 cases is shown in supplementary Figure S1 , available at Annals of Oncology online. The mean/median TTAC was 10 and 9 weeks, respectively. Twenty-three percent (120/533) of patients started ACT >12 weeks after surgery. Variables associated with initiating ACT >12 weeks after surgery are shown in Table 2 . Patients older than 70 years of age were more likely to have delayed TTAC relative to patients <50 years. Patients with node-positive disease were less likely to have delayed TTAC than those with node-negative disease. Patients from the poorest communities were more likely to have delayed TTAC than those from the most affluent communities. These results were consistent with linear regression evaluating TTAC as a continuous variable (data not shown).
outcomes Among patients treated with NACT (n = 129), 5-year OS was 25% [95% confidence interval (CI) 17% to 34%] and CSS was 28% (95% CI 18% to 39%); corresponding figures for ACT patients (n = 541) were 29% (95% CI 25% to 33%) and 28% (95% CI 24% to 33%), respectively (supplementary Figure S2 , available at Annals of Oncology online).
Factors associated with survival are shown in Table 3 . Advanced T and N stage of disease and the presence of lymphovascular invasion were associated with inferior OS and CSS. TTAC >12 weeks was associated with inferior OS [hazard ratio (HR) 1.28, 95% CI 1.00-1.62] and CSS (HR 1.30, 95% CI 1.00-1.69). These results were consistent when TTAC was modeled as a continuous variable (unit = 1 week) (OS HR 1.03, 95% CI 1.00-1.07; CSS HR 1.04, 95% CI 1.00-1.08) (supplementary Table S1 , available at Annals of Oncology online).
An exploratory analysis was carried out to evaluate the potential association between ACT regimen and survival discussion Several reports, including our own study in Ontario, have described low utilization rates of perioperative chemotherapy for bladder cancer [1] [2] [3] [4] [5] . In this population-based study, we have evaluated specific aspects related to the delivery of perioperative chemotherapy in routine clinical practice. A number of important findings have emerged. First, consistent with the clinical trial literature, most patients in Ontario who receive perioperative chemotherapy are treated with cisplatin-based regimens, with a minority receiving carboplatin. Second, the specific chemotherapy regimens have evolved over time: MVAC was used commonly in the 1990s but has now been replaced largely by gemcitabine-cisplatin. Third, adjuvant chemotherapy is often delayed: 23% start treatment >12 weeks after cystectomy. Our data show a substantial association between timing of ACT initiation and patient outcome. Fourth, survival of patients treated with NACT and ACT in the general population is substantially lower than the relevant clinical trials. Finally, the results of an exploratory analysis suggest that use of carboplatin-based adjuvant chemotherapy is associated with inferior outcomes compared with cisplatin. Using the SEER-Medicare database, Porter et al. a similar shift in practice away from MVAC and towards gemcitabinecisplatin [3] . That corresponds temporally to a pivotal clinical trial in the setting of advanced disease [19] . In Porter's study, 22% of chemotherapy claims after 2002 included carboplatin whereas 14% of patients in our study were treated with carboplatin.
The use of carboplatin in the perioperative context is not driven by level 1 evidence but reflects the practical reality that many patients with resectable MIBC are not eligible for cisplatin-based chemotherapy due to renal impairment. Previous reports have suggested that up to 50% of patients are not eligible for perioperative cisplatin due to renal dysfunction [20, 21] . In a meta-analysis of 286 patients with metastatic urothelial carcinoma from four RCTs, Galsky et al. found that the likelihood of achieving a complete response was substantially higher (RR 3.54, 95% CI 1.48-8.49) with cisplatin-versus carboplatin-based therapy [22] . A nonsignificant trend toward reduced mortality at 12 months was observed for cisplatin (RR 0.78, 95% CI 0.56-1.07). This analysis was likely underpowered to detect a significant difference. We are unaware of comparative studies of cisplatin and carboplatin in the perioperative setting. In our own exploratory analysis of 257 patients, carboplatin-based therapy was associated with substantially lower OS and CSS.
The time interval from surgery to initiation of ACT has been found to be associated with OS and CSS in breast and colorectal cancers [12] [13] [14] . Most clinical trials mandate that ACT start within 8 weeks of surgery; reports from routine clinical practice show that a substantial proportion of patients are not treated within this time period. In our recent meta-analysis of TTAC and colorectal cancer [14] , we found that a 4-week increase in [26, 27] and/or enhance production of oncogenic growth factors [28] . The TTAC effect is also consistent with the Goldie and Coldman model [29] . Within the urologic literature are numerous reports that describe an association between greater mortality and increased delay between transurethral bladder tumor resection and cystectomy [30] . The outcomes of patients treated in our study population are substantially worse than those reported in the relevant clinical trials. Five-year OS of NACT patients (26%) in the current study was 26% compared with rates of 49% and 57% reported in the two pivotal RCTs [8, 9] . Survival of patients treated with ACT (29% at 5 years) is also much lower than the advanced bladder cancer meta-analysis which was closer to 50% [31] . These observed differences may relate to selection and referral biases; differences in surgical technique (e.g. utilization of pelvic lymphadenectomy); and the known association between greater cystectomy case volumes and improved outcomes [32] . The fact that 67% of patients in our study population treated with ACT had node-positive disease suggests they had more advanced disease compared with those in clinical trials [10] .
While our study provides novel insights into use of perioperative chemotherapy for bladder cancer in routine practice, it has several methodological limitations. Although the data sources used in this study describe general aspects of disease, treatment and outcome for all patients in Ontario, detailed information related to chemotherapy administration, treatment toxicity and performance status is not available for all patients. This limits our ability to evaluate the appropriateness of case selection for NACT/ACT. Details of the chemotherapy regimen were only available for those patients treated at comprehensive cancer centers (46% of ACT cases). Furthermore, the available records did not permit us to identify dose and number of cycles. Because patient-level chart information was not available, we used a modified Charlson co-morbidity index that has been adapted for administrative purposes [18] . Finally, our finding that survival is associated with the timing of ACT and cisplatin versus carboplatin regimen may be biased by the presence of unmeasured confounders.
In summary, our results demonstrate that most patients treated with perioperative chemotherapy for bladder cancer in the general population receive cisplatin-based therapy and that this may be associated with improved outcomes compared with carboplatin. Initiation of ACT relative to surgery is longer than in clinical trials and is associated with a reduction in OS and CSS. Patients should start ACT in the postoperative period as soon as they are medically fit to do so. Outcomes achieved in routine clinical practice are substantially inferior to those reported in clinical trials. Further efforts are required to 
